RT Journal Article
SR Electronic
T1 Increased vaccine sensitivity of an emerging SARS-CoV-2 variant
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.11.23287148
DO 10.1101/2023.03.11.23287148
A1 Lewnard, Joseph A.
A1 Hong, Vennis
A1 Kim, Jeniffer S.
A1 Shaw, Sally F.
A1 Lewin, Bruno
A1 Takhar, Harpreet
A1 Lipsitch, Marc
A1 Tartof, Sara Y.
YR 2023
UL http://medrxiv.org/content/early/2023/03/16/2023.03.11.23287148.abstract
AB Host immune responses are a key source of selective pressure driving pathogen evolution. Emergence of many SARS-CoV-2 lineages has been associated with improvements in their ability to evade population immunity resulting from both vaccination and infection. Here we show diverging trends of escape from vaccine-derived and infection-derived immunity for the emerging XBB/XBB.1.5 Omicron lineage. Among 31,739 patients tested in ambulatory settings in Southern California from December, 2022 to February, 2023, adjusted odds of prior receipt of 2, 3, 4, and ≥5 COVID-19 vaccine doses were 10% (95% confidence interval: 1-18%), 11% (3-19%), 13% (3-21%), and 25% (15-34%) lower, respectively, among cases infected with XBB/XBB.1.5 than among cases infected with other co-circulating lineages. Similarly, prior vaccination was associated with greater protection against progression to hospitalization among cases with XBB/XBB.1.5 than among non-XBB/XBB.1.5 cases (70% [30-87%] and 48% [7-71%], respectively, for recipients of ≥4 doses). In contrast, cases infected with XBB/XBB.1.5 had 17% (11-24%) and 40% (19-65%) higher adjusted odds of having experienced 1 and ≥2 prior documented infections, respectively, including with pre-Omicron variants. As immunity acquired from SARS-CoV-2 infection becomes increasingly widespread, fitness costs associated with enhanced vaccine sensitivity in XBB/XBB.1.5 may be offset by increased ability to evade infection-derived host responses.Competing Interest StatementJAL has received research grants paid directly to his institution and consulting honoraria unrelated to this study from Pfizer. SYT has received research grants paid directly to her institution unrelated to this study from Pfizer. The remaining authors disclose no competing interests.Funding StatementThis work was funded by the US Centers for Disease Control and Prevention (CDC; grant 75D3-121C11520 to SYT). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. JAL was supported by grant R01-AI14812701A1 from the National Institute for Allergy and Infectious Diseases (US National Institutes of Health), which had no role in design or conduct of the study, or the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Kaiser Permanente Southern California Institutional Review Board reviewed and provided ethical approval for the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesIndividual-level testing and clinical outcomes data reported in this study are not publicly shared. Individuals wishing to access disaggregated data, including data reported in this study, should submit requests for access to the corresponding author (sara.y.tartof{at}kp.org). De-identified data (including, as applicable, participant data and relevant data dictionaries) will be shared upon approval of analysis proposals with signed data-access agreements in place.